Form 8-K - Current report:
SEC Accession No. 0001558370-22-018890
Filing Date
2022-12-21
Accepted
2022-12-21 16:30:14
Documents
12
Period of Report
2022-12-20
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K sgtx-20221220x8k.htm   iXBRL 8-K 35874
  Complete submission text file 0001558370-22-018890.txt   159169

Data Files

Seq Description Document Type Size
2 EX-101.SCH sgtx-20221220.xsd EX-101.SCH 2953
3 EX-101.LAB sgtx-20221220_lab.xml EX-101.LAB 16581
4 EX-101.PRE sgtx-20221220_pre.xml EX-101.PRE 10455
6 EXTRACTED XBRL INSTANCE DOCUMENT sgtx-20221220x8k_htm.xml XML 5097
Mailing Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142
Business Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142 617-336-7540
Sigilon Therapeutics, Inc. (Filer) CIK: 0001821323 (see all company filings)

EIN.: 474005543 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39746 | Film No.: 221478767
SIC: 2834 Pharmaceutical Preparations